EAS Newsletter August 13, 2024
Education: Liver and lipids in cardiometabolic syndrome: our official joint session at ESC Congress 2024 We are thrilled to invite you to our official joint…
Author: Mateusz Szwachta
The role of dietary lipid quality for the prevention of atherosclerotic cardiovascular disease (ASCVD)
There is still an ongoing debate about the role of dietary lipids in the context of ASCVD prevention although there are clear guidelines for dietary…
EAS Newsletter August 6, 2024
Publications: EAS Consensus position statements are readily available at your fingertips The EAS Consensus Panel, comprised of internationally renowned experts in atherosclerosis and cardiovascular disease,…
EAS Newsletter July 30, 2024
Society: Apply for an EAS Competitive grant before it’s too late Submit your application for an EAS Competitive Grant before the deadline on September 13,…
EAS Newsletter July 23, 2024
Society: Don’t let this opportunity pass you by. Apply for an EAS Competitive grant Don’t let this opportunity pass you by! Submit your application for…
EAS Newsletter July 16, 2024
Society: Don’t let this opportunity pass you by. Apply for an EAS Competitive grant Don’t let this opportunity pass you by! Submit your application for…
Dietary counselling for blood cholesterol from infancy to young adulthood: CVD risk prevention should start at early age
Atherosclerotic cardiovascular disease (ASCVD) remains to be the leading cause of mortality and disabilityworldwide. Atherosclerosis, the underlying cause of cardiovascular disease (CVD), begins early in…
EAS Newsletter July 9, 2024
Governance: Announcing the newly elected Executive Committee members We are delighted to announce the winners of the 2024 Executive Committee election. We extend our sincere…
Election results 2024
We are pleased to announce the conclusion of the EAS 2024 elections and extend our congratulations to the following individuals: Post of Vice-President 2025-2028Jeanine Roeters…
Featured Open Lecture: July-August 2024
Gene therapy in lipid metabolism and CVD by Prof Sekar Kathiresan Sekar Kathiresan is the Chief Executive Officer and founder of Verve Therapeutics, US. Previously,…